1 21 4

Shareholder Tools

Home Investor Relations

Investor Relations

  1. Chart
  2. Quote
Stock price graph
+ 0.44
Day High:
Day Low:
4:00 PM ET on Jul 31, 2015

Delayed at least 20 minutes.
Provided by eSignal.

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. MacroGenics creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines. The combination of MacroGenics’ technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.

Corporate Fact Sheet

Corporate Fact Sheet

PDF  Corporate Fact Sheet

View all »   RSSRecent Releases

Jul 29, 2015
MacroGenics Announces Date of Second Quarter 2015 Financial Results Conference Call

Jul 28, 2015
MGD011 Advances Into Clinical Development

View all »Events & Presentations

Aug 5, 2015 at 4:30 PM ET
MacroGenics, Inc. Second Quarter 2015 Financial Results Conference Call